Illumina Stock News

Aegon Asset Management UK PLC increased its position in Illumina, Inc. (NASDAQ:ILMN) by 2.7% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 185,386 shares of the life sciences companys stock after acquiring an additional 4,851 shares during the period. Illumina makes up about 1.1% of Aegon Asset Management UK PLCs investment portfolio, making []

Illumina's (ILMN) recent collaboration will allow it to leverage the best-quality synthetic data to remove privacy bottlenecks and accelerate the development of precision medicine.

Hills Bank & Trust Co lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 6.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,410 shares of the life sciences companys stock after purchasing an additional 324 shares during the quarter. []

Pune, India, Dec. 14, 2021 (GLOBE NEWSWIRE) -- The global next-generation sequencing market size is expected to gain momentum by reaching USD 31,411.3 million by 2026 while exhibiting a CAGR of 22.2% between 2019 to 2026. In its report titled "Next Generation Sequencing Market, 2019-2026.", Fortune Business Insight s mentions that the market stood at USD 6,335.2 million in 2018. The rising demand for cost-effective and accurate DNA sequencing to treat genetic diseases is expected to drive the market. Moreover, the launch of several genomic projects in countries such as Qatar and the U.K with able support from the government is expected to fuel the market in upcoming years. Industry Developments January 2019 : PierianDx announced its partnership with Illumina to come up with informatics services such as oncology products for Illumina to support cancer diagnosis and research. Request for Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/sample/next-generation-sequencing-ngs-market-101000 Driving Factors Growing Focus on Diagnosis of Diseases Globally to Augment Growth Lower costs of sequencing solutions have resulted in the high demand for the diagnosis of several diseases.

Key Companies in Next-Generation Sequencing Market are Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, BGI, PerkinElmer Inc., Eurofins Scientific, Macrogen, Inc., PierianDx Key Companies in Next-Generation Sequencing Market are Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., QIAGEN, BGI, PerkinElmer Inc., Eurofins Scientific, Macrogen, Inc., PierianDx

The global Life Science and Chemical Instrumentation market size is projected to reach US$ 43080 million by 2026, from US$ 40760 million in 2020, at a CAGR of 5.3%% during 2021-2026. The major vendors covered: Agilent Technologies Inc, Bio-Rad Laboratories Inc, Becton, Dickinson, & Company, Bruker Corporation, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Illumina Inc, PerkinElmer Inc, Danaher Corporation, Shimadzu Corporation, Waters Corporation The global Life Science and Chemical Instrumentation market size is projected to reach US$ 43080 million by 2026, from US$ 40760 million in 2020, at a CAGR of 5.3%% during 2021-2026. The major vendors covered: Agilent Technologies Inc, Bio-Rad Laboratories Inc, Becton, Dickinson, & Company, Bruker Corporation, Thermo Fisher Scientific Inc, F. Hoffmann-La Roche Ltd, Illumina Inc, PerkinElmer Inc, Danaher Corporation, Shimadzu Corporation, Waters Corporation

JJJ Advisors Inc. grew its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 25.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 151 shares of the life sciences companys stock after purchasing an additional 31 shares during the period. JJJ Advisors Inc.s holdings []

Patton Fund Management Inc. purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, Holdings Channel.com reports. The firm purchased 2,665 shares of the life sciences companys stock, valued at approximately $1,081,000. A number of other hedge funds and other institutional investors have also made changes to their positions in the []

Equities analysts expect that Illumina, Inc. (NASDAQ:ILMN) will announce earnings per share of $0.46 for the current quarter, Zacks reports. Three analysts have issued estimates for Illuminas earnings. The highest EPS estimate is $0.52 and the lowest is $0.40. Illumina reported earnings of $1.22 per share in the same quarter last year, which would indicate []

Which stocks are entering into a strong seasonal period in the upcoming days? The Seasonax screener function will automatically generate a list of the

Equities analysts expect Illumina, Inc. (NASDAQ:ILMN) to post $1.09 billion in sales for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Illuminas earnings, with the highest sales estimate coming in at $1.10 billion and the lowest estimate coming in at $1.09 billion. Illumina posted sales of $953.00 million in the same []

The long read sequencing market in SAM is expected to grow from US$ 40.53 million in 2021 to US$ 150.44 million by 2028; it is estimated to grow at a CAGR of 20.6% from 2021 to 2028. A report added on

Another factual information on the "Global Bioinformatics Market" has as of late added by CMI to its storehouse. This global research report offers an inside and out examination of various perspectives, for example, global market patterns, pieces of the overall

Sicart Associates LLC lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 9.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,843 shares of the life sciences companys stock after selling 1,272 shares during the period. Illumina makes up about 1.4% of []